Pulmonary Fibrosis Foundation Expands Care Center Network to 96 Sites

The Pulmonary Fibrosis Foundation’s Care Center Network has expanded to include 96 sites across 40 states, marking its first growth since 2023. This expansion aims to strengthen access to specialized care for individuals living with pulmonary fibrosis (PF) and interstitial lung disease (ILD).

Frequently Asked Questions

What is the PFF Care Center Network?

The PFF Care Center Network includes medical centers that meet rigorous criteria developed with input from ILD experts and patient representatives. Each center offers a multidisciplinary team of specialists.

How many fresh sites were added to the network?

Eleven new medical centers have been designated as part of the PFF Care Center Network. One site, St. Luke’s University Health Network in Bethlehem, Pennsylvania, transitioned from a Clinical Associate to a Care Center.

What is the difference between a Care Center and a Clinical Associate?

Clinical Associate members of the CCN collaborate with Care Centers, providing access to resources and referrals for patients who do not live near a designated Care Center.

According to Sonye Danoff, Senior Medical Advisor for the PFF Care Center Network, “The continued development of the PFF Care Center Network is helping transform how patient care is delivered for people living with life-threatening, progressive lung diseases.” The expansion supports the Foundation’s strategic plan to improve care for patients nationwide.

Newly designated sites include Intermountain Health Interstitial Lung Disease Clinic in Salt Lake City, Utah, and the University of Mississippi Medical Center Interstitial Lung Disease Program in Jackson, Mississippi. A full list of the 96 sites is available.

The Pulmonary Fibrosis Foundation is committed to accelerating research and empowering the PF community. More information can be found at pulmonaryfibrosis.org or by calling 844.TalkPFF (844.825.5733).

As the PFF Care Center Network continues to grow, what impact might this have on the speed of research and development of new treatments for pulmonary fibrosis?